Market Access

Engaging the full workforce—from HR to R&D—can elevate launch outcomes, build trust, and create long-term brand ambassadors.

In the third part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, proposes ways to ensure both fiscal responsibility and the sustainability of hospital funding.

The US president says the levies on pharmaceutical imports are imminent, but won’t take effect for a year to a year and a half.

In the second part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, outlines how the federal cap on Medicaid provider taxes could affect access to care for Medicaid patients.

Amid the push for reshoring and fiscal reform, the tariffs are part of a broader effort to rebalance trade and fund domestic initiatives, as the pharma sector awaits potential levies of its own.

A qualitative study explores how MA plan leaders, kidney care managers, and dialysis providers perceive the benefits, risks, and marketing practices surrounding MA enrollment for patients with end-stage kidney disease.

In the first part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, explains how a federal cap on Medicaid provider taxes could potentially impact hospital systems.

As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.

State Medicaid leaders create a plan to ensure safety, affordability, and equitable access for children and families living with rare diseases.

Analysis compares care quality and efficiency within physician groups that treat Medicare Advantage patients under at-risk contracts, versus fee-for-service.

In the second part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains how recent shifts in FDA leadership, funding constraints, and evolving CMC standards have each played a role in this process.

When automatically moved from a zero-dollar silver plan to one that requires a premium due to plan turnover, do lower-income health insurance marketplace enrollees lose or switch coverage?

In the final part of her Pharma Commerce video interview, LeAnn Boyd, Liviniti’s founder and CEO, describes what meaningful drug pricing reform looks like to her.

A cross-sectional study investigates whether becoming eligible for Medicare at age 65 is linked to changes in healthcare use among individuals experiencing mental health challenges.

In the third part of her Pharma Commerce video interview, LeAnn Boyd, Liviniti’s founder and CEO, explains how a flat admin fee model can potentially create more value for both payers and patients.

Is Medicare plan switching influenced by initial type of Medicare coverage and cancer history?

In the second part of her Pharma Commerce video interview, LeAnn Boyd, Liviniti’s founder and CEO, discusses how this MFN executive order can affect players in the space that operate under a rebate-driven PBM model.

Though this specific agreement centers around aerospace and automobiles, the greater supply chain will wait and see how Trump’s import taxes impact pharmaceuticals, a sector that faces a potential 25% tax on imports.

In the first part of her Pharma Commerce video interview, LeAnn Boyd, Liviniti’s founder and CEO, outlines the most critical root causes of rising healthcare and drug costs that the MFN executive order doesn’t address.

An exploration into how flawed incentives and contractual loopholes between manufacturers and pharmacy benefit managers played their part.

How practical is this form of pricing in the pharma setting?

In the final part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, illustrates how data-driven insights can support PBMs and healthcare leaders in negotiating fairer drug prices?

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

A cross-sectional study explores how full-benefit dual-eligible beneficiaries differ across MA plans with differing levels of Medicaid coordination and integration.

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’